Company Description
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs).
The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis.
The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases.
It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage.
The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis.
The company was incorporated in 2020 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 2020 |
| IPO Date | Dec 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Howard Berman Ph.D. |
Contact Details
Address: 12645 Memorial Dr., Suite F1 #305 Houston, Texas 77024 United States | |
| Phone | 650.739.3939 |
| Website | coyatherapeutics.com |
Stock Details
| Ticker Symbol | COYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001835022 |
| ISIN Number | US22407B1089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Howard Berman Ph.D. | Chairman and Chief Executive Officer |
| Dr. Fred Grossman D.O., FAPA | President and Chief Medical Officer |
| David S. Snyder | Chief Financial Officer and Chief Operating Officer |
| Dr. Gregory MacMichael Ph.D. | Chief Technical Officer |
| Dr. Michelle Frazier Ph.D. | Senior Vice President of Regulatory Affairs |
| Aaron Thome Ph.D. | Head of Neuroinflammation Platform |
| Dr. Arun Swaminathan Ph.D. | Chief Business Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2024 | ARS | Filing |
| Mar 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 19, 2024 | 10-K | Annual Report |
| Mar 19, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 19, 2024 | 8-K | Current Report |
| Jan 16, 2024 | 424B3 | Prospectus |